S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NYSEAMERICAN:PTN

Palatin Technologies (PTN) Stock Price, News & Analysis

$1.87
+0.27 (+16.88%)
(As of 03/28/2024 ET)
Today's Range
$1.61
$1.92
50-Day Range
N/A
52-Week Range
$1.43
$5.65
Volume
395,574 shs
Average Volume
535,883 shs
Market Capitalization
$30.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Palatin Technologies MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
809.1% Upside
$17.00 Price Target
Short Interest
Bearish
9.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.50mentions of Palatin Technologies in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$23,400 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.36) to ($0.66) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.33 out of 5 stars

PTN stock logo

About Palatin Technologies Stock (NYSEAMERICAN:PTN)

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

PTN Stock Price History

PTN Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
PTN Apr 2024 2.500 put
PTN Apr 2024 7.500 call
Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Palatin Technologies, Inc. (PTN)
Q2 2024 Palatin Technologies Inc Earnings Call
The 3 Best Penny Stocks to Buy in February 2024
See More Headlines
Receive PTN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:PTN
Employees
34
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.00
High Stock Price Target
$17.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+834.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-27,540,000.00
Net Margins
-445.12%
Pretax Margin
-503.33%

Debt

Sales & Book Value

Annual Sales
$4.85 million
Book Value
$0.01 per share

Miscellaneous

Free Float
14,894,000
Market Cap
$29.37 million
Optionable
Not Optionable
Beta
0.94
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Carl Spana Ph.D. (Age 62)
    Co-Founder, President, CEO & Director
    Comp: $979k
  • Mr. Stephen T. Wills CPA (Age 67)
    MST, CFO, COO, Executive VP, Treasurer & Secretary
    Comp: $910.55k
  • Burns McClellan
    Vice President of Investor Relations
  • Mr. Stephen A. Slusher Esq.
    Chief Legal Officer
  • Dr. Michael B. Raizman M.D.
    Chief Medical Officer
  • Mr. James E. Hattersley (Age 64)
    Senior Vice President of Business Development
  • Mr. John Dodd Ph.D.
    Senior Vice President of Preclinical Development
  • Mr. Robert Jordan
    Senior Vice President of Program Operations

PTN Stock Analysis - Frequently Asked Questions

Should I buy or sell Palatin Technologies stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTN shares.
View PTN analyst ratings
or view top-rated stocks.

What is Palatin Technologies' stock price target for 2024?

1 analysts have issued 12 month price objectives for Palatin Technologies' shares. Their PTN share price targets range from $17.00 to $17.00. On average, they expect the company's share price to reach $17.00 in the next year. This suggests a possible upside of 809.1% from the stock's current price.
View analysts price targets for PTN
or view top-rated stocks among Wall Street analysts.

How have PTN shares performed in 2024?

Palatin Technologies' stock was trading at $4.00 at the beginning of 2024. Since then, PTN stock has decreased by 53.3% and is now trading at $1.87.
View the best growth stocks for 2024 here
.

Are investors shorting Palatin Technologies?

Palatin Technologies saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 1,450,000 shares, an increase of 25.0% from the February 29th total of 1,160,000 shares. Based on an average daily trading volume, of 552,700 shares, the days-to-cover ratio is currently 2.6 days. Approximately 9.4% of the shares of the company are short sold.
View Palatin Technologies' Short Interest
.

When is Palatin Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our PTN earnings forecast
.

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) released its quarterly earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.36. The biopharmaceutical company had revenue of $2.03 million for the quarter, compared to analyst estimates of $2.28 million. Palatin Technologies had a negative net margin of 445.12% and a negative trailing twelve-month return on equity of 583.06%. During the same period in the previous year, the firm posted ($0.13) EPS.

When did Palatin Technologies' stock split?

Palatin Technologies shares reverse split before market open on Wednesday, August 31st 2022. The 1-25 reverse split was announced on Wednesday, August 31st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 31st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Palatin Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM).

Who are Palatin Technologies' major shareholders?

Palatin Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (4.29%), Vanguard Group Inc. (3.40%), Vanguard Group Inc. (3.99%), Northern Trust Corp (0.18%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alan W Dunton, Robert K Deveer Jr and Stephen T Wills.
View institutional ownership trends
.

How do I buy shares of Palatin Technologies?

Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:PTN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners